New research reveals that specialized gut bacteria convert bile acids into powerful healing compounds, offering hope for ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Body mass index did not impact the safety and efficacy of etrasimod in patients with ulcerative colitis, according to 2 studies.

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

One in three Australians with inflammatory bowel disease (IBD) left their medical consultations with misunderstandings about ...

Morgan Stanley assumed coverage of Abivax (ABVX) with an Equal Weight rating and $12 price target The Phase 2 results for obefazimod, Abivax’s ...

Treatment for microscopic colitis usually involves medication to reduce symptoms. Learn about medication types and other ...

This study highlights the link between plant-based diets and reduced IBD risk, suggesting dietary choices play a crucial role ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...